AIBD 2019
Worsening Symptoms, Heart Failure in UC Patient Treated With Mesalamine
The patient had been diagnosed with mild-to-moderate ulcerative colitis (UC) a month prior to presentation for which she was prescribed oral mesalamine.
Your search for tofacitinib returned 15 results
AIBD 2019
Combination Biologics or Small Molecules vs Biologic Monotherapy in IBD
The following article is a part of conference coverage from the 2019 Advances in Inflammatory Bowel Diseases (AIBD) Meeting, being held in Orlando, Florida. The team at MPR will be reporting on the latest news and research conducted by leading experts gastroenterology. Check back for more from the 2019 AIBD Meeting. Combination biologic therapy may…
AIBD 2019
Timing of Biologic/JAK Inhibitor Treatment Initiation in IBD Patients Examined
According to new research over 1 in 5 patients with inflammatory bowel disease (IBD) should have started treatment with an advanced systemic therapy earlier in their disease.
AIBD 2019
Tofacitinib vs Vedolizumab: Short-Term Efficacy Compared in Ulcerative Colitis
In patients with ulcerative colitis (UC), tofacitinib, a Janus kinase inhibitor, was associated with improved short-term efficacy, when compared with vedolizumab, an integrin receptor antagonist. Findings were presented at the Advances in Inflammatory Bowel Disease (AIBD) 2019 meeting in Orlando, Florida.
AIBD 2019
Case Highlights Novel Approach to Treatment of UC, Psoriatic Arthritis
A recently published report presented at the 2019 AIBD Annual Meeting in Orlando, FL, discussed the case of a patient who developed ulcerative colitis (UC) following treatment with Secukinumab for her psoriatic arthritis and highlighted a novel approach for the management of both of her conditions simultaneously.
AIBD 2019
Impact of Tofacitinib on Extraintestinal Symptoms in UC Patients Examined
Treatment with tofacitinib appears to have little impact on extraintestinal manifestations (EIMs) in patients with moderate to severe ulcerative colitis (UC) and might even improve them, according to an analysis of the OCTAVE program. Findings were presented at the 2019 AIBD Annual Meeting in Orlando, Florida.
ACR/ARHP 2018 Annual Meeting
Obesity Negatively Affects Treatment Response to JAK Inhibitors in RA
Patients treated with JAK inhibitors for rheumatoid arthritis may be less likely to have low disease activity if they are obese compared with those who are overweight.
ACR/ARHP 2017 Annual Meeting
Can Anemia Predict Radiographic Progression in Tofacitinib Treated RA Patients?
In this post hoc analysis, researchers explored whether anemia was a predictor of radiographic progression in patients with RA who were treated with tofacitinib.
EULAR 2017
Tofacitinib Goes Head-to-Head with Adalimumab in Rheumatoid Arthritis Study
Xeljanz and Xeljanz XR are Janus kinase (JAK) inhibitors indicated to treat moderately to severely active rheumatoid arthritis when methotrexate therapy is inadequate.
ACR/ARHP 2016 Annual Meeting
Tofacitinib Effective in PsA Patients With Prior Inadequate Response
Statistically significant improvements were shown 3 months vs. placebo with tofacitinib, in this new study
